Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.| MedCity News
This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.| KFF
Those new weight-loss drugs will slash spending on obesity-related illness, so why is it so hard to get insurers to cover them?| Los Angeles Times
This analysis of survey data finds that over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug though relatively few have a claim, suggesting that a much smaller share seeks treatment through healthcare providers.| Peterson-KFF Health System Tracker
GLP-1s are showing dramatic results in reducing addictive drive while providing holistic mental health benefits to patients.| recursiveadaptation.com
Ozempic (semaglutide) is used for type 2 diabetes, to reduce the risk of cardiovascular events, and may help weight loss. Ozempic dose, side effects, and use.| Drugs.com
This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.| KFF
New indication for patients with obesity or overweight and a history of cardiovascular disease| www.medpagetoday.com